Nirsevimab Reduces Disease Burden In Pediatric Patients With RSV, Review Suggests

Infectious Disease Advisor (7/9, Nye) reports a systematic review and meta-analysis suggests that “nirsevimab effectively reduces the burden of respiratory syncytial virus (RSV) infection among infants and young children.” The researchers selected 32 studies for the review, “of which 27 were included in the meta-analysis.” They observed that “among infants aged 12 months and younger, pooled analyses indicated nirsevimab was associated with decreased risk for RSV-related hospitalization, ICU admission, and LRTI.” Furthermore, subgroup analyses revealed that “nirsevimab more effectively reduced risk for RSV-related hospitalization in infants older than 3 months than in those aged 3 months and younger. However, the difference in risk was not significant.” The review was published in The Lancet Child & Adolescent Health.